Citable filing context
CAH's research view summarizes recent SEC filing context, starting with debt_offering from Aug 11, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 11, 2026 | debt_offering | Cardinal Health entered into a new $4.0 billion unsecured revolving credit facility expiring in 2031. |
| Aug 11, 2026 | earnings | Cardinal Health reported fourth quarter and fiscal year 2026 results and provided fiscal year 2027 guidance. |
| Aug 5, 2026 | management_change | Cardinal Health appointed Anita Zielinski as Chief Accounting Officer, effective November 5, 2026. |
| Aug 11, 2026 | Guidance: global_medical_products_and_distribution_revenue_growth | 2.00 to 4.00 |
| Aug 11, 2026 | Guidance: global_medical_products_and_distribution_segment_profit | 200.00 to 220.00 |
| Aug 11, 2026 | Guidance: non_gaap_adjusted_free_cash_flow | 3500.00 to 4000.00 |
| Aug 11, 2026 | business | Cardinal Health is a global healthcare services and products company operating through three primary segments: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other. The Pharmaceutical and Specialty Solutions segment, the company’s largest, distributes branded and generic pharmaceuticals and provides management services to physician practices through its Managed Service Organization (MSO) platforms, including The Specialty Alliance and Navista. The GMPD segment manufactures and sources Cardinal Health-branded medical, surgical, and laboratory products, while the Other segment encompasses at-Home solutions, nuclear pharmacy services, and logistics. Fiscal 2026 revenue reached $254.2 billion, a 14% increase driven by branded and specialty pharmaceutical sales. Non-GAAP operating earnings rose 30% to $3.6 billion, bolstered by MSO acquisitions and generic program performance. However, the company faces significant risks, including intense competition, high customer concentration—with CVS Health accounting for 28% of revenue—and a complex regulatory environment involving the DEA, FDA, and various anti-kickback statutes. The company is also navigating a volatile tariff landscape, including potential future tariffs on generic pharmaceuticals, and managing long-term opioid litigation settlements. Strategic focus remains on expanding specialty offerings through acquisitions, such as the $1.9 billion Solaris Health purchase, while managing debt and capital allocation. |
| Aug 11, 2026 | mda | Cardinal Health reported strong fiscal 2026 performance, with revenue increasing 14% to $254.2 billion, driven by branded and specialty pharmaceutical sales. Non-GAAP operating earnings rose 30% to $3.6 billion, bolstered by the performance of the Pharma segment’s generics program and the integration of Management Service Organization (MSO) platforms, specifically the $1.9 billion acquisition of Solaris Health. The Pharma segment remains the primary growth engine, though it faces headwinds from the Inflation Reduction Act’s drug price caps and potential future tariffs on generic pharmaceuticals. A notable operational challenge included a $184 million goodwill impairment charge related to the Navista & ION oncology unit, reflecting updated business model assumptions. The Global Medical Products and Distribution (GMPD) segment saw a 91% increase in segment profit, aided by the resolution of IEEPA tariff disputes, which resulted in a net benefit after customer repayments. Despite this, the company remains exposed to a volatile tariff environment across its global supply chain. Liquidity remains robust, with $4.9 billion in cash and equivalents. Capital deployment focused on MSO acquisitions, $1.4 billion in share repurchases, and ongoing payments related to national opioid litigation settlements, which are expected to continue through 2038. |
Source: SEC EDGAR filing text and events; period Aug 11, 2026; filed Aug 11, 2026.
CAH company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.